Eli Lilly and Co
LLY1077.520USD
+0.540+0.05%
終値 12/26, 16:00（ET）15分遅れの株価
1.02T時価総額
52.57直近12ヶ月PER
詳細情報 Eli Lilly and Co 企業名
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures and markets products in the human pharmaceutical products segment. Its cardiometabolic health products include Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound; VERVE-102; VERVE-201, and VERVE-301. Its oncology products include Cyramza, Erbitux, Tyvyt, and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. The Company, through its subsidiary, POINT Biopharma Global Inc., is engaged in radiopharmaceutical discovery, development, and manufacturing efforts, as well as clinical and pre-clinical radioligand therapies in development for the treatment of cancer. It is also developing an oral small molecule inhibitor of a4b7 integrin for inflammatory bowel disease (IBD).
Eli Lilly and Coの企業情報
企業コードLLY
会社名Eli Lilly and Co
上場日Jul 09, 1970
最高経営責任者「CEO」Ricks (David A)
従業員数47000
証券種類Ordinary Share
決算期末Jul 09
本社所在地Lilly Corporate Ctr
都市INDIANAPOLIS
証券取引所NASDAQ OMX NASDAQ Basic NYSE
国United States of America
郵便番号46285
電話番号13172762000
ウェブサイトhttps://www.lilly.com/
企業コードLLY
上場日Jul 09, 1970
最高経営責任者「CEO」Ricks (David A)
Eli Lilly and Coの経営陣
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. J. Erik Fyrwald
Mr. J. Erik Fyrwald
Independent Director
Independent Director
74.57K
+0.30%
Ms. Anne E. White
Ms. Anne E. White
Executive Vice President, President - Lilly Neuroscience
Executive Vice President, President - Lilly Neuroscience
74.21K
+13.18%
Mr. Patrik Jonsson
Mr. Patrik Jonsson
Executive Vice President, President of Lilly Cardiometabolic Health and President, Lilly USA
Executive Vice President, President of Lilly Cardiometabolic Health and President, Lilly USA
54.13K
+20.12%
Mr. Edgardo Hernandez
Mr. Edgardo Hernandez
Executive Vice President, President - Manufacturing Operations
Executive Vice President, President - Manufacturing Operations
39.73K
-0.04%
Mr. Ilya Yuffa
Mr. Ilya Yuffa
Executive Vice President, President of Lilly International
Executive Vice President, President of Lilly International
26.26K
-4.54%
Ms. Anat Hakim
Ms. Anat Hakim
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
25.66K
-41.06%
Dr. Katherine Baicker, Ph.D.
Dr. Katherine Baicker, Ph.D.
Independent Director
Independent Director
23.37K
+0.93%
Mr. Diogo Rau
Mr. Diogo Rau
Executive Vice President, Chief Information and Digital Officer
Executive Vice President, Chief Information and Digital Officer
19.72K
+77.63%
Mr. Lucas E. Montarce
Mr. Lucas E. Montarce
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
14.69K
+5.12%
Mr. Eric Dozier
Mr. Eric Dozier
Executive Vice President, Chief People Officer
Executive Vice President, Chief People Officer
9.84K
+15.72%
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. J. Erik Fyrwald
Mr. J. Erik Fyrwald
Independent Director
Independent Director
74.57K
+0.30%
Ms. Anne E. White
Ms. Anne E. White
Executive Vice President, President - Lilly Neuroscience
Executive Vice President, President - Lilly Neuroscience
74.21K
+13.18%
Mr. Patrik Jonsson
Mr. Patrik Jonsson
Executive Vice President, President of Lilly Cardiometabolic Health and President, Lilly USA
Executive Vice President, President of Lilly Cardiometabolic Health and President, Lilly USA
54.13K
+20.12%
Mr. Edgardo Hernandez
Mr. Edgardo Hernandez
Executive Vice President, President - Manufacturing Operations
Executive Vice President, President - Manufacturing Operations
39.73K
-0.04%
Mr. Ilya Yuffa
Mr. Ilya Yuffa
Executive Vice President, President of Lilly International
Executive Vice President, President of Lilly International
26.26K
-4.54%
Ms. Anat Hakim
Ms. Anat Hakim
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
25.66K
-41.06%
収益内訳
通貨: USD更新時刻: Mon, Oct 6
通貨: USD更新時刻: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
事業別USD
会社名
収益
比率
Diabetes-Mounjaro
5.20B
33.42%
Diabetes-Zepbound
3.38B
21.73%
Oncology-Verzenio
1.49B
9.57%
Diabetes-Trulicity
1.09B
7.02%
Diabetes-Other Diabetes
980.40M
6.30%
他の
3.42B
21.95%
地域別USD
会社名
収益
比率
U.S.
10.81B
69.51%
Europe
2.57B
16.55%
Other foreign countries
1.18B
7.60%
Japan
521.00M
3.35%
China
465.90M
2.99%
事業別
地域別
事業別USD
会社名
収益
比率
Diabetes-Mounjaro
5.20B
33.42%
Diabetes-Zepbound
3.38B
21.73%
Oncology-Verzenio
1.49B
9.57%
Diabetes-Trulicity
1.09B
7.02%
Diabetes-Other Diabetes
980.40M
6.30%
他の
3.42B
21.95%
株主
更新時刻: Wed, Nov 12
更新時刻: Wed, Nov 12
株主統計
種類
株主統計
株主統計
比率
Lilly Endowment, Inc.
9.75%
The Vanguard Group, Inc.
8.52%
PNC Investments LLC
5.41%
BlackRock Institutional Trust Company, N.A.
4.43%
State Street Investment Management (US)
3.67%
他の
68.21%
株主統計
株主統計
比率
Lilly Endowment, Inc.
9.75%
The Vanguard Group, Inc.
8.52%
PNC Investments LLC
5.41%
BlackRock Institutional Trust Company, N.A.
4.43%
State Street Investment Management (US)
3.67%
他の
68.21%
種類
株主統計
比率
Investment Advisor
45.38%
Investment Advisor/Hedge Fund
18.69%
Foundation
9.75%
Research Firm
2.04%
Pension Fund
1.89%
Bank and Trust
1.84%
Insurance Company
1.48%
Sovereign Wealth Fund
1.29%
Hedge Fund
0.74%
他の
16.90%
機関投資家保有株
更新時刻: Wed, Oct 1
更新時刻: Wed, Oct 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q3
5762
789.85M
83.53%
-6.48M
2025Q2
5717
798.76M
84.28%
+2.87M
2025Q1
5710
800.38M
84.44%
+5.04M
2024Q4
5528
795.43M
83.87%
+627.51K
2024Q3
5177
793.57M
83.49%
-5.03M
2024Q2
5068
795.80M
83.72%
-2.01M
2024Q1
4916
795.04M
83.62%
-6.22M
2023Q4
4670
799.46M
84.21%
-2.37M
2023Q3
4354
800.21M
84.30%
-1.19M
2023Q2
4197
799.48M
84.22%
-4.32M
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
Lilly Endowment, Inc.
95.49M
10.09%
-243.99K
-0.25%
Sep 30, 2025
The Vanguard Group, Inc.
80.05M
8.46%
+1.17M
+1.49%
Jun 30, 2025
PNC Investments LLC
51.08M
5.4%
-9.49K
-0.02%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
41.30M
4.36%
-168.44K
-0.41%
Jun 30, 2025
State Street Investment Management (US)
34.51M
3.65%
+69.02K
+0.20%
Jun 30, 2025
Capital Research Global Investors
20.76M
2.19%
+5.01M
+31.81%
Jun 30, 2025
Fidelity Management & Research Company LLC
24.36M
2.57%
-2.82M
-10.39%
Jun 30, 2025
Geode Capital Management, L.L.C.
18.13M
1.92%
-397.62K
-2.15%
Jun 30, 2025
Capital World Investors
17.63M
1.86%
-748.08K
-4.07%
Jun 30, 2025
Wellington Management Company, LLP
13.99M
1.48%
+1.28M
+10.09%
Jun 30, 2025
詳細を見る
関連ETF
更新時刻: Sat, Dec 6
更新時刻: Sat, Dec 6
銘柄名
比率
VanEck Pharmaceutical ETF
47.56%
iShares U.S. Pharmaceuticals ETF
25.23%
Harbor Health Care ETF
18.24%
Roundhill GLP-1 & Weight Loss ETF
16.7%
Health Care Select Sector SPDR Fund
14.06%
Proshares Ultra Health Care
13.57%
iShares U.S. Healthcare ETF
13.54%
Amplify Weight Loss Drug & Treatment ETF
11.93%
Fidelity MSCI Health Care Index ETF
11.73%
Goldman Sachs Future Health Care Equity ETF
10.84%
詳細を見る
VanEck Pharmaceutical ETF
比率47.56%
iShares U.S. Pharmaceuticals ETF
比率25.23%
Harbor Health Care ETF
比率18.24%
Roundhill GLP-1 & Weight Loss ETF
比率16.7%
Health Care Select Sector SPDR Fund
比率14.06%
Proshares Ultra Health Care
比率13.57%
iShares U.S. Healthcare ETF
比率13.54%
Amplify Weight Loss Drug & Treatment ETF
比率11.93%
Fidelity MSCI Health Care Index ETF
比率11.73%
Goldman Sachs Future Health Care Equity ETF
比率10.84%
配当金
過去5年間の配当金総支払額は
18.06B
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
Oct 27, 2025
LLY.NB Final Cash Dividend of gross USD 1.5 paid on Dec 10, 2025 going ex on Nov 14, 2025
Nov 14, 2025
Dec 10, 2025
Nov 14, 2025
Jun 23, 2025
LLY.NB Interim Cash Dividend of gross USD 1.5 paid on Sep 10, 2025 going ex on Aug 15, 2025
Aug 15, 2025
Sep 10, 2025
Aug 15, 2025
May 05, 2025
LLY.NB Interim Cash Dividend of gross USD 1.5 paid on Jun 10, 2025 going ex on May 16, 2025
May 16, 2025
Jun 10, 2025
May 16, 2025
Dec 09, 2024
LLY.NB Interim Cash Dividend of gross USD 1.5 paid on Mar 10, 2025 going ex on Feb 14, 2025
Feb 14, 2025
Mar 10, 2025
Feb 14, 2025
Oct 28, 2024
LLY.NB Final Cash Dividend of gross USD 1.3 paid on Dec 10, 2024 going ex on Nov 15, 2024
Nov 15, 2024
Dec 10, 2024
Nov 15, 2024
Jun 24, 2024
LLY.NB Interim Cash Dividend of gross USD 1.3 paid on Sep 10, 2024 going ex on Aug 15, 2024
Aug 15, 2024
Sep 10, 2024
Aug 15, 2024
May 06, 2024
LLY.NB Interim Cash Dividend of gross USD 1.3 paid on Jun 10, 2024 going ex on May 15, 2024
May 16, 2024
Jun 10, 2024
May 15, 2024
Dec 08, 2023
LLY.NB Interim Cash Dividend of gross USD 1.3 paid on Mar 08, 2024 going ex on Feb 14, 2024
Feb 15, 2024
Mar 08, 2024
Feb 14, 2024
Nov 01, 2023
LLY.NB Final Cash Dividend of gross USD 1.13 paid on Dec 08, 2023 going ex on Nov 14, 2023
Nov 15, 2023
Dec 08, 2023
Nov 14, 2023
Jun 26, 2023
LLY.NB Interim Cash Dividend of gross USD 1.13 paid on Sep 08, 2023 going ex on Aug 14, 2023
Aug 15, 2023
Sep 08, 2023
Aug 14, 2023
詳細を見る
株式分割
日付
種類
比率
データなし
日付
種類
比率
データなし
よくある質問
Eli Lilly and Coの上位5名の株主は誰ですか？
Eli Lilly and Coの上位5名の株主は以下のとおりです。
Lilly Endowment, Inc.は95.49M株を保有しており、これは全体の10.09%に相当します。
The Vanguard Group, Inc.は80.05M株を保有しており、これは全体の8.46%に相当します。
PNC Investments LLCは51.08M株を保有しており、これは全体の5.40%に相当します。
BlackRock Institutional Trust Company, N.A.は41.30M株を保有しており、これは全体の4.36%に相当します。
State Street Investment Management (US)は34.51M株を保有しており、これは全体の3.65%に相当します。
Lilly Endowment, Inc.は95.49M株を保有しており、これは全体の10.09%に相当します。
The Vanguard Group, Inc.は80.05M株を保有しており、これは全体の8.46%に相当します。
PNC Investments LLCは51.08M株を保有しており、これは全体の5.40%に相当します。
BlackRock Institutional Trust Company, N.A.は41.30M株を保有しており、これは全体の4.36%に相当します。
State Street Investment Management (US)は34.51M株を保有しており、これは全体の3.65%に相当します。
Eli Lilly and Coの株主タイプ上位3種は何ですか？
Eli Lilly and Coの株主タイプ上位3種は、
Lilly Endowment, Inc.
The Vanguard Group, Inc.
PNC Investments LLC
Lilly Endowment, Inc.
The Vanguard Group, Inc.
PNC Investments LLC
Eli Lilly and Co（LLY）の株式を保有している機関の数はいくつですか？
2025Q3時点で、Eli Lilly and Coの株式を保有している機関は5762社あり、保有株式の総市場価値は約789.85Mで、全体の83.53%を占めています。2025Q2と比較して、機関の持ち株は-0.75%増加しています。
Eli Lilly and Coの最大の収益源は何ですか？
FY2025Q2において、Diabetes-Mounjaro部門がEli Lilly and Coにとって最大の収益を生み出しており、その金額は5.20Bで、全収益の33.42%を占めています。
